Shannon Puhalla
YOU?
Author Swipe
View article: Longitudinal ctDNA Surveillance in Older Women with ER+ Breast Cancer to Facilitate Surgical De-Escalation: A Prospective, Hybrid-Decentralized Trial with Correlative Studies
Longitudinal ctDNA Surveillance in Older Women with ER+ Breast Cancer to Facilitate Surgical De-Escalation: A Prospective, Hybrid-Decentralized Trial with Correlative Studies Open
For older patients with competing comorbidities, optimizing oncologic therapies is of paramount importance. Circulating tumor DNA (ctDNA) is a validated prognostic factor across solid tumors and may provide a strategy to identify patients …
View article: Hope for OTHERS (Our Tissue Helping Enhance Research & Science): research results from the University of Pittsburgh rapid autopsy program for breast cancer
Hope for OTHERS (Our Tissue Helping Enhance Research & Science): research results from the University of Pittsburgh rapid autopsy program for breast cancer Open
Breast cancer affects 1/8 of women throughout their lifetimes, with over 90% of cancer deaths being caused by metastasis. However, metastasis poses unique challenges to research, as complex changes in the microenvironment in different meta…
View article: Hope for Others: Research Results from the University of Pittsburgh Rapid Autopsy Program for Breast Cancer
Hope for Others: Research Results from the University of Pittsburgh Rapid Autopsy Program for Breast Cancer Open
Breast cancer affects 1/8 of women throughout their lifetimes, with over 90% of cancer deaths being caused by metastasis. However, metastasis poses unique challenges to research, as complex changes in the microenvironment in different meta…
View article: Research autopsy programmes in oncology: shared experience from 14 centres across the world
Research autopsy programmes in oncology: shared experience from 14 centres across the world Open
While there is a great clinical need to understand the biology of metastatic cancer in order to treat it more effectively, research is hampered by limited sample availability. Research autopsy programmes can crucially advance the field thr…
View article: Supplementary Data from Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER<sup>+</sup>/HER2<sup>−</sup> Breast Cancer
Supplementary Data from Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER<sup>+</sup>/HER2<sup>−</sup> Breast Cancer Open
Supplementary Data from Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER+/HER2− Breast Cancer
View article: Data from Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER<sup>+</sup>/HER2<sup>−</sup> Breast Cancer
Data from Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER<sup>+</sup>/HER2<sup>−</sup> Breast Cancer Open
Purpose:To determine (i) the relationship between candidate biomarkers of the antiproliferative (Ki67) response to letrozole and palbociclib alone and combined in ER+/HER2− breast cancer; and (ii) the pharmacodynamic …
View article: Supplementary Data from Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER<sup>+</sup>/HER2<sup>−</sup> Breast Cancer
Supplementary Data from Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER<sup>+</sup>/HER2<sup>−</sup> Breast Cancer Open
Supplementary Data from Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER+/HER2− Breast Cancer
View article: Supplementary Data from Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER<sup>+</sup>/HER2<sup>−</sup> Breast Cancer
Supplementary Data from Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER<sup>+</sup>/HER2<sup>−</sup> Breast Cancer Open
Supplementary Data from Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER+/HER2− Breast Cancer
View article: Supplementary Data from Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER<sup>+</sup>/HER2<sup>−</sup> Breast Cancer
Supplementary Data from Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER<sup>+</sup>/HER2<sup>−</sup> Breast Cancer Open
Supplementary Data from Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER+/HER2− Breast Cancer
View article: Data from Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER<sup>+</sup>/HER2<sup>−</sup> Breast Cancer
Data from Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER<sup>+</sup>/HER2<sup>−</sup> Breast Cancer Open
Purpose:To determine (i) the relationship between candidate biomarkers of the antiproliferative (Ki67) response to letrozole and palbociclib alone and combined in ER+/HER2− breast cancer; and (ii) the pharmacodynamic …
View article: A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620)
A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620) Open
View article: 179 T-cells derived from malignant pleural effusions (MPE) are readily expandable, polyfunctional and cytotoxic to autologous tumor
179 T-cells derived from malignant pleural effusions (MPE) are readily expandable, polyfunctional and cytotoxic to autologous tumor Open
Background We have shown that malignant pleural effusions (MPE) are characterized by a distinct and complex pleural secretome1–3 dominated by IL-6, sIL-6Rα, CCL2, CXCL10, TGFβ, CCL22, IL-8. These cytokines favor tumor epithelial…
View article: INTRAPLEURAL THERAPY TO DISRUPT IL-6/IL-8 JUXTACTINE SIGNALLING TO BLOCK TUMOR EMT AND TO DRIVE SYSTEMIC ANTI-TUMOR IMMUNITY
INTRAPLEURAL THERAPY TO DISRUPT IL-6/IL-8 JUXTACTINE SIGNALLING TO BLOCK TUMOR EMT AND TO DRIVE SYSTEMIC ANTI-TUMOR IMMUNITY Open
Objective: The goal of this study was to determine whether antiIL-6Rα block (tocilizumab) will alter the pleural secretome and will diminish tumor-specific immune responses. Methodology: Pleural T cells were isolated from freshly drained p…
View article: A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer
A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer Open
View article: Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer:subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial
Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer:subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial Open
Purpose: To evaluate efficacy and safety of veliparib combined with carboplatin/paclitaxel in patients with advanced human epidermal growth factor receptor 2 (HER2)-negative, germline BRCA (gBRCA)-associated breast cancer defined by hormon…
View article: Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors
Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors Open
View article: 140O Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: Results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial
140O Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: Results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial Open
View article: TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer
TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer Open
Background In preclinical studies, the expression of vascular endothelial growth factor (VEGF) in hormone receptor-positive breast cancer is associated with estrogen-independent tumor growth and resistance to endocrine therapies. This stud…
View article: Additional file 5 of TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer
Additional file 5 of TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer Open
Additional file 5. Appendix 2. Summary statistics for all tested small RNA features in sequencing data (sorted by letozole/bevacizumab responder P).
View article: Additional file 4 of TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer
Additional file 4 of TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer Open
Additional file 4. Appendix 1. LASSO selected classifiers and qPCR assay information.
View article: Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies
Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies Open
View article: Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer
Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer Open
NCT01268150 (December 29, 2010), NCT01269346 (January 4, 2011).
View article: Targeted mutation detection in breast cancer using MammaSeq™
Targeted mutation detection in breast cancer using MammaSeq™ Open
View article: Additional file 7: of Targeted mutation detection in breast cancer using MammaSeqâ ˘
Additional file 7: of Targeted mutation detection in breast cancer using MammaSeqâ ˘ Open
Data file 2 Single nucleotide variants detected by MammaSeq in solid tumors. (XLSX 255 kb)
View article: Additional file 10: of Targeted mutation detection in breast cancer using MammaSeqâ ˘
Additional file 10: of Targeted mutation detection in breast cancer using MammaSeqâ ˘ Open
Data file 3 Single nucleotide variants detected by MammaSeq in cfDNA. (XLSX 60 kb)
View article: Additional file 2: of Targeted mutation detection in breast cancer using MammaSeqâ ˘
Additional file 2: of Targeted mutation detection in breast cancer using MammaSeqâ ˘ Open
Data file 1 Genomic location of mutations in MammaSeq panel. (XLSX 113 kb)
View article: Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial
Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial Open
PURPOSE CDK4/6 inhibitors are used to treat estrogen receptor (ER)–positive metastatic breast cancer (BC) in combination with endocrine therapy. PALLET is a phase II randomized trial that evaluated the effects of combination palbociclib pl…
View article: Whole genome amplification of cell-free DNA enables detection of circulating tumor DNA mutations from fingerstick capillary blood
Whole genome amplification of cell-free DNA enables detection of circulating tumor DNA mutations from fingerstick capillary blood Open
View article: Targeted Mutation Detection in Advanced Breast Cancer Using MammaSeq Identifies RET as a Potential Contributor to Breast Cancer Metastasis
Targeted Mutation Detection in Advanced Breast Cancer Using MammaSeq Identifies RET as a Potential Contributor to Breast Cancer Metastasis Open
The lack of any reported breast cancer specific diagnostic NGS tests inspired the development of MammaSeq, an amplicon based NGS panel built specifically for use in advanced breast cancer. In a pilot study to define the clinical utility of…
View article: Targeted mutation detection in breast cancer using MammaSeq™
Targeted mutation detection in breast cancer using MammaSeq™ Open
Background Breast cancer is the most common invasive cancer among women worldwide. Next-generation sequencing (NGS) has revolutionized the study of cancer across research labs around the globe, however genomic testing in clinical settings …